Trial Profile
A Japanese Multicenter, Open Label, Phase I Trial of c-Met Inhibitor MSC2156119J Given Orally as Monotherapy to Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Tepotinib (Primary)
- Indications Advanced breast cancer; Anal cancer; Appendiceal cancer; Biliary cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Rectal cancer; Solid tumours; Thoracic neoplasms
- Focus Adverse reactions
- Sponsors Merck KGaA
- 01 Jul 2022 Results of a pooled exposure-efficacy analyses included data from an ongoing phase 2 study (VISION) and 4 completed studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992) investigating 500 mg/day tepotinib in NSCLC harboring METex14 skipping alterations published in the Cancer Chemotherapy and Pharmacology
- 21 Sep 2020 Results of a pooled analysis of data from from four completed phase I/II studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373) and one ongoing phase II study (VISION, NCT02864992) assessing the relationship between tepotinib and both safety and efficacy endpoints in patients with solid tumours, presented at the 45th European Society for Medical Oncology Congress
- 04 Aug 2020 Results published in the Japanese Journal of Clinical Oncology